Metformin cuts cardio events in high-risk type 2 diabetes

Metformin cuts cardio events in high-risk type 2 diabetes
Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

(HealthDay)—Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

Jie Hong, M.D., from the Shanghai Jiao Tong University School of Medicine, and colleagues conducted a multicenter trial in which 304 patients with type 2 diabetes with (mean age, 63.3 years) were randomized to receive glipizide (30 mg daily) or metformin (1.5 g daily) for three years. The composite end point was times to recurrent , including death from a cardiovascular cause, death from any cause, nonfatal , nonfatal stroke, or arterial revascularization.

The researchers found that both groups achieved a significant reduction in the level of glycated hemoglobin (7.1 percent in the glipizide group and 7.0 percent in the metformin group). Ninety-one participants developed 103 primary end points over a median follow-up of five years. The adjusted hazard ratio for the composites of cardiovascular events among the patients that received metformin versus glipizide was 0.54. There was no significant difference between the two groups for secondary end points and adverse events.

"Treatment with metformin for three years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide," the authors write.

The glipizide and metformin were provided by the Xinyi Pharmaceutical Co.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Sulfonylureas up cardio events versus metformin

date Nov 07, 2012

(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue ...

Imeglimin beneficial as add-on to metformin in T2DM

date Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Recommended for you

Diabetes drug helps people lose weight: study

date Jul 01, 2015

Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), a yearlong study said Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.